BA-015(BA-015) - 药物靶点：α5β1 x αvβ3_专利_临床

概要

基本信息

药物类型

基因疗法

别名

AMEP、Plasmid AMEP、Synfoldin

+ [5]

靶点

α5β1 x αvβ3

作用方式

拮抗剂

作用机制

α5β1拮抗剂(整合素α-5/β-1复合体拮抗剂)、αvβ3拮抗剂(整合素α-V/β-3复合体拮抗剂)

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

转移性黑色素瘤

原研机构

Valerio Therapeutics SA

在研机构-

非在研机构

Valerio Therapeutics SA

权益机构-

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 BA-015 相关的临床试验

NCT01764009

/ Withdrawn临床1/2期

Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open-label Phase I/II Clinical Trial - The AIMM Study (AMEP In Metastatic Melanoma)

The objective of the present trial is:
to determine the dose limiting toxicity (DLT), maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of intramuscular electrotransferred Plasmid AMEP in patients with advanced or metastatic melanoma.
to determine the local and general safety of intramuscular electrotransferred Plasmid AMEP
to evaluate the efficacy of intramuscular electrotransferred Plasmid AMEP

开始日期2012-06-01

申办/合作机构

Valerio Therapeutics SA

NCT01045915

/ Terminated临床1期

Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial

The objective of the present trial is to evaluate the local and general safety of the intratumoural electrotransfer of increasing doses of Plasmid AMEP in patients suffering from advanced or metastatic melanoma and to identify doses that could be effective on cutaneous lesions in man.

开始日期2010-07-01

申办/合作机构

Valerio Therapeutics SA

100 项与 BA-015 相关的临床结果

登录后查看更多信息

100 项与 BA-015 相关的转化医学

登录后查看更多信息

100 项与 BA-015 相关的专利（医药）

登录后查看更多信息

12

项与 BA-015 相关的文献（医药）

2023-11-01·Fish & Shellfish Immunology

Effects of dietary bile acids levels on growth performance, anti-oxidative capacity, immunity and intestinal microbiota of abalone Haliotis discus hannai

Article

作者: Zhang, Wenbing ; Chen, Peng ; Liu, Chang ; Wu, Zhenhua ; Mai, Kangsen ; Cui, Zhengyi ; Lei, Keke ; Tian, Shuangjie

Abalone Haliotis discus hannai (initial weight: 38.79 ± 0.70 g) was used as the experimental animal in a 105-day feeding trial to investigate the influence of dietary bile acids levels on the growth, anti-oxidation, immune response and intestinal microbiota. Six isonitrogenous and isolipidic diets were prepared by adding 0 (control group), 15, 30, 60, 120 and 240 mg/kg of bile acids, respectively (named BA0, BA15, BA30, BA60, BA120 and BA240, respectively). It was found that survival of abalone between groups had no significant difference (P > 0.05). Compared to the control, significant improvements in weight gain rate (WGR) were observed in the groups of BA30 and BA60 (P < 0.05). Based on WGR, the broken line regression model analysis showed that the optimum demand for dietary bile acids for abalone was 35.47 mg/kg. Dietary bile acids increased the total anti-oxidative capacity and activities of catalase, superoxide dismutase, lysozyme and alkaline phosphatase, meanwhile decreased the content of malondialdehyde, alanine aminotransferase and aspartate aminotransferase activities in the cell-free hemolymph (P < 0.05). When bile acids were added to the diets, mRNA levels of genes related to pro-inflammatory factors and apoptosis in the digestive gland were down-regulated (P < 0.05). In contrast, the expression of genes related to anti-oxidation was significantly up-regulated (P < 0.05). The Firmicutes, Actinobacteriota and Proteobacteria were the most abundant phyla in intestine. And dietary bile acids significantly decreased the abundance of Actinobacteria and increased the abundance of Firmicutes (P < 0.05). In conclusion, supplementation of dietary bile acids within 120 mg/kg significantly increased the growth of abalone. The 34.62 mg/kg of dietary bile acids significantly increased the anti-oxidative capacity of abalone. Appropriate levels of dietary bile acids (34.62-61.75 mg/kg) promote the immunity of abalone. Application of appropriate levels of bile acids in diets (34.62 mg/kg) changed the intestinal microbiota and promoted the intestinal health of abalone.

2023-07-27·BMC infectious diseases

Alternative boronic acids in the detection of Mycolactone A/B using the thin layer chromatography (f-TLC) method for diagnosis of Buruli ulcer.

Article

作者: Amewu, Richard K ; Akolgo, Gideon A ; D Craggs, Timothy ; Partridge, Benjamin M

BACKGROUNDMycobacterium ulcerans is the causative agent of Buruli ulcer. The pathology of M. ulcerans disease has been attributed to the secretion of a potent macrolide cytotoxin known as mycolactone which plays an important role in the virulence of the disease. Mycolactone is a biomarker for the diagnosis of BU that can be detected using the fluorescent-thin layer chromatography (f-TLC) technique. The technique relies on the chemical derivatization of mycolactone A/B with 2-naphthylboronic acid (BA) which acts as a fluorogenic chemosensor. However, background interferences due to co-extracted human tissue lipids, especially with clinical samples coupled with the subjectivity of the method call for an investigation to find an alternative to BA.METHODSTwenty-six commercially available arylboronic acids were initially screened as alternatives to BA using the f-TLC experiment. UV-vis measurements were also conducted to determine the absorption maximum spectra of mycolactone A/B and myco-boronic acid adducts followed by an investigation of the fluorescence-enhancing ability of the boronate ester formation between mycolactone A/B and our three most promising boronic acids (BA15, BA18, and BA21). LC-MS technique was employed to confirm the adduct formation between mycolactone and boronic acids. Furthermore, a comparative study was conducted between BA18 and BA using 6 Polymerase Chain Reaction (PCR) confirmed BU patient samples.RESULTSThree of the boronic acids (BA15, BA18, and BA21) produced fluorescent band intensities superior to BA. Complexation studies conducted on thin layer chromatography (TLC) using 0.1 M solution of the three boronic acids and various volumes of 10 ng/µL of synthetic mycolactone ranging from 1 µL - 9 µL corresponding to 10 ng - 90 ng gave similar results with myco-BA18 adduct emerging with the most visibly intense fluorescence bands. UV-vis absorption maxima (λ_max) for the free mycolactone A/B was observed at 362 nm, and the values for the adducts myco-BA15, myco-BA18, and myco-BA21 were at 272 nm, 270 nm, and 286 nm respectively. The comparable experimental λ_max of 362 nm for mycolactone A/B to the calculated Woodward-Fieser value of 367 nm for the fatty acid side chain of mycolactone A/B demonstrate that even though 2 cyclic boronates were formed, only the boronate of the southern side chain with the chromophore was excited by irradiation at 365 nm. Fluorescence experiments have demonstrated that coupling BA18 to mycolactone A/B along the 1,3-diols remarkably enhanced the fluorescence intensity at 537 nm. High-Resolution Mass Spectrometer (HR-MS) was used to confirm the formation of the myco-BA15 adduct. Finally, f-TLC analysis of patient samples with BA18 gave improved BA18-adduct intensities compared to the original BA-adduct.CONCLUSIONTwenty-six commercially available boronic acids were investigated as alternatives to BA, used in the f-TLC analysis for the diagnosis of BU. Three (3) of them BA15, BA18, and BA21 gave superior fluorescence band intensity profiles. They gave profiles that were easier to interpret after the myco-boronic acid adduct formation and in experiments with clinical samples from patients with BA18 the best. BA18, therefore, has been identified as a potential alternative to BA and could provide a solution to the challenge of background interference of co-extracted human tissue lipids from clinical samples currently associated with the use of BA.

2021-11-01·Carbohydrate Polymers1区 · 化学

Exfoliated bentonite/alginate nanocomposite hydrogel enhances intestinal delivery of probiotics by resistance to gastric pH and on-demand disintegration

1区 · 化学

Article

作者: Kim, Min-Soo ; Kim, Sangsik ; Moon, Hyung Ryong ; Kim, Jihyun ; Hlaing, Shwe Phyu ; Yoon, In-Soo ; Hwang, Dong Soo ; Lee, Eun Hee ; Yoo, Jin-Wook ; Saparbayeva, Aruzhan ; Lee, Juho ; Yun, Hwayoung ; Jung, Yunjin

In this study, we developed Lactobacillus rhamnosus GG (LGG)-encapsulating exfoliated bentonite/alginate nanocomposite hydrogels for protecting probiotics by delaying gastric fluid penetration into the nanocomposite and their on-demand release in the intestine. The pore size of the bentonite/alginate nanocomposite hydrogels (BA15) was two-fold smaller than that of alginate hydrogel (BA00). Following gastric pH challenge, the survival of LGG in BA15 decreased by only 1.43 log CFU/g as compared to the 6.25 log CFU/g decrease in alginate (BA00). Further, the internal pH of BA15 decreased more gradually than that of BA00. After oral administration in mice, BA15 maintained shape integrity during gastric passage, followed by appropriate disintegration within the target intestinal area. Additionally, a fecal recovery experiment in mice showed that the viable counts of LGG in BA15 were six-fold higher than those in BA00. The findings suggest the exfoliated bentonite/alginate nanocomposite hydrogel as a promising platform for intestinal delivery of probiotics.

100 项与 BA-015 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性黑色素瘤	临床2期	斯洛文尼亚	Valerio Therapeutics SA	2012-06-01
转移性黑色素瘤	临床2期	法国	Valerio Therapeutics SA	2012-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASGCT2010	临床1期	黑色素瘤	-	Plasmid AMEP	(築選夢鹽製繭鹹襯鹹蓋) = no body weight loss 鹹廠廠鑰遞窪繭選壓鑰 (製顧繭糧範糧觸製積獵 )	积极	2010-05-01
ASGCT2010	临床1期	黑色素瘤	-	Temozolomide	(築選夢鹽製繭鹹襯鹹蓋) = no body weight loss 鹹廠廠鑰遞窪繭選壓鑰 (製顧繭糧範糧觸製積獵 )	积极	2010-05-01
ASGCT2010	N/A	黑色素瘤	-	Plasmid AMEP	鑰襯餘鏇鬱積簾膚鹹艱(願夢範範構夢醖糧艱醖) = 蓋製壓壓憲艱遞艱製範鏇鏇鏇鑰餘餘醖鹹窪醖 (鹽繭製壓網衊製艱鏇夢 ) 更多	-	2010-05-01
AACR2009	临床1期	转移性黑色素瘤	-	p-AMEP plasmid	鑰憲築網積積願窪夢鬱(齋窪蓋廠顧醖窪鹽繭醖) = 鑰築蓋鬱繭憲鬱構鏇顧窪鏇鹽簾壓顧繭顧齋觸 (衊積範鬱製積醖鬱鬱衊 ) 更多	-	2009-05-01